Adam Kaiser
Pulmonary Disease · North Chesterfield, VANPI 1972823177
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,170 of the $67,207 with a category attached, or 71.7%. AstraZeneca accounts for 77.1% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2022 at $25,379 and has fallen 90.4% since, to $2,429 in 2023. Among pulmonary disease clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 267 payments — averaging $251.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$52K
- Regeneron Healthcare Solutions, Inc.$8K
- Amgen$2K
- Medtronic$2K
- Veran Medical Technologies, Inc.$1K
- Boehringer Ingelheim$326
- plus $2K from 21 others
What the payments were for
- Consulting fees$8,15912%
- Speaking & faculty fees$48,17072%
- Travel & lodging$4,8657%
- Food & beverage$5,8969%
- Education$1170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 92 | $51,824 |
| Regeneron Healthcare Solutions, Inc. | 29 | $8,226 |
| Amgen | 9 | $2,063 |
| Medtronic | 13 | $1,991 |
| Veran Medical Technologies, Inc. | 4 | $1,173 |
| Boehringer Ingelheim | 18 | $326 |
| GSK | 31 | $308 |
| Actelion Pharmaceuticals US, Inc. | 9 | $158 |
| Sanofi | 9 | $148 |
| Johnson & Johnson | 1 | $117 |
| Mylan Specialty L.p. | 7 | $111 |
| Philips North America LLC | 7 | $111 |
| Genentech USA, Inc. | 10 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $82 |
| Insmed, Inc. | 6 | $76 |
| Grifols USA, LLC | 3 | $70 |
| Inogen, Inc. | 3 | $61 |
| Phadia US Inc. | 2 | $48 |
| Intuitive Surgical | 1 | $44 |
| Paratek Pharmaceuticals, Inc. | 2 | $42 |
| Mallinckrodt Hospital Products Inc. | 2 | $41 |
| Covis Pharma GmbH | 1 | $26 |
| Merck | 1 | $17 |
| Novartis | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Baxter Healthcare | 1 | $14 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$38,750
- TEZSPIRE$8,250
- DUPIXENT$5,047
- ILLUMISITE$1,892
- Spin$1,173
- LINX Reflux Management System$117
How this compares
$67,207 in reported general payments places this provider in the 90th percentile of 317 pulmonary disease providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $28,340 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $8,056 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $3,485 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 40 | $1,051 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta | $308 | $36,39643 claims |
| AstraZenecaSymbicort | $51,824 | $3,48516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in North Chesterfield
- Muhammad AtharNorth Chesterfield$25K
- Alice HerlihyNorth Chesterfield$18K
- Steven NathanFalls Church$1.5M
- Omar MinaiHopewell$1.3M
- Rabih HalabiFalls Church$604K
- Eric LibreAnnandale$302K
- Sujoy GillRichmond$296K
- Imre NothCharlottesville$256K
- Carlos SilvaChesapeake$245K
- Vijay SubramaniamWilliamsburg$228K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.